SLGL — Sol-Gel Technologies Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1684693 ·
Israel
Last close
$70.36
Market Cap
$228.34M
52W High
$93.53
52W Low
$61.92
ADV30
34,108
Next earnings
2026-08-21
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 108,000 | — | -3,855,000 | -3,727,000 | 58,550,000 | 10,136,000 | 7,144,000 |
| Dec 2025 | 696,000 | — | -3,411,000 | -2,987,000 | 29,917,000 | 11,033,000 | 7,106,000 |
| Sep 2025 | 400,000 | — | -6,288,000 | -5,942,000 | 34,592,000 | 6,705,000 | 8,562,000 |
| Jun 2025 | 17,261,000 | — | 11,230,000 | 11,610,000 | 39,307,000 | 10,221,000 | 7,425,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-237,010,000
Inventory
—
Receivables
$1,968,000
ST Investments
$12,966,000
EBIT TTM
$10,600,000
Pretax Income TTM
$-6,127,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,465,000
EBITDA
$-2,300,000
Free Cash Flow
$617,000
Enterprise Value
$186,245,376
Total Cash
$52,828,000
Total Debt
$862,000
Shares Out
3,245,270
Trailing EPS
$-0.30
Book Value
$15.72
ROE
-2.9%
ROA
-3.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,388,000 | -7,538,000 | -6,127,000 | 29,917,000 | 7,106,000 | — | 322,000 |
| Dec 2024 | 11,538,000 | -12,014,000 | -10,580,000 | 35,846,000 | 6,996,000 | — | -13,889,000 |
| Dec 2023 | 1,554,000 | -29,305,000 | -27,238,000 | 45,287,000 | 6,643,000 | — | -17,730,000 |
| Dec 2022 | 3,883,000 | -16,244,000 | -14,923,000 | 46,628,000 | 4,415,000 | — | -9,484,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-10.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HELP | CYBIN INC. | $228.52M | $4.58 | — |
| NGEN | NERVGEN PHARMA CORP. | $232.58M | $2.19 | — |
| FULC | Fulcrum Therapeutics, Inc. | $233.22M | $3.50 | — |
| ADAG | Adagene Inc. | $233.24M | $3.53 | — |
| FHTX | Foghorn Therapeutics Inc. | $237.79M | $4.05 | — |
News headlines (Yahoo Finance, 1h cache)
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
2026-05-28 13:10 · Yahoo
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-28 12:00 · Yahoo
US Equity Indexes Fall Amid Uncertainty Over US-Iran Truce Talks
2026-03-24 20:48 · Yahoo
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
2026-03-24 01:38 · Yahoo
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
2026-03-19 18:00 · Yahoo
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
2026-03-19 12:53 · Yahoo
Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year
2026-02-11 18:23 · Yahoo
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth
2025-12-29 12:41 · Yahoo
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
2025-12-17 12:00 · Yahoo
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
2025-11-20 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.